Falk E: Pathogenesis of atherosclerosis. Am Heart J. 1999, 138: S421-S425. 10.1016/S0002-8703(99)70267-X.
Creemers EE, Cleutjens JP, Smits JF, Daemen MJ: Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure. Circ Res. 2001, 89: 201-210. 10.1161/hh1501.094396.
Dollery CM, Libby P: Atherosclerosis and proteinase activation. Cardiovasc Res. 2006, 69: 625-635. 10.1016/j.cardiores.2005.11.003.
Sluijter JP, de Kleijn DP, Pasterkamp G: Vascular remodeling and protease inhibition–bench to bedside. Cardiovasc Res. 2006, 69: 595-603. 10.1016/j.cardiores.2005.11.026.
Messerli FH: TIMPs, MMPs and cardiovascular disease. Eur Heart J. 2004, 25: 1475-1476. 10.1016/j.ehj.2004.07.015.
Jones CB, Sane DC, Herrington DM: Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc Res. 2003, 59: 812-823. 10.1016/S0008-6363(03)00516-9.
Newby AC: Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev. 2005, 85: 1-31. 10.1152/physrev.00048.2003.
Galis ZS, Sukhova GK, Lark MW, Libby P: Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994, 94: 2493-2503. 10.1172/JCI117619.
Nikkari ST, O’Brien KD, Ferguson M: Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. Circulation. 1995, 92: 1393-1398. 10.1161/01.CIR.92.6.1393.
Sukhova GK, Schonbeck U, Rabkin E: Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation. 1999, 99: 2503-2509. 10.1161/01.CIR.99.19.2503.
Morgan AR, Rerkasem K, Gallagher PJ: Differences in matrix metalloproteinase-1 and matrix metalloproteinase-12 transcript levels among carotid atherosclerotic plaques with different histopathological characteristics. Stroke. 2004, 35: 1310-1315. 10.1161/01.STR.0000126822.01756.99.
Galt SW, Lindemann S, Allen L: Outside-in signals delivered by matrix metalloproteinase-1 regulate platelet function. Circ Res. 2002, 90: 1093-1099. 10.1161/01.RES.0000019241.12929.EB.
Nakamura T, Ushiyama C, Suzuki S, Ebihara I, Shimada N, Koide H: Elevation of serum levels of metalloproteinase-1, tissue inhibitor of metalloproteinase-1 and type IV collagen, and plasma levels of metalloproteinase-9 in polycystic kidney disease. Am J Nephrol. 2000, 20: 32-36. 10.1159/000013552.
Rosas IO, Richards TJ, Konishi K: MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med. 2008, 5: e93-10.1371/journal.pmed.0050093.
Naito Y, Tsujino T, Lee-Kawabata M: Matrix metalloproteinase-1 and -2 levels are differently regulated in acute exacerbation of heart failure in patients with and without left ventricular systolic dysfunction. Hear Vessel. 2009, 24: 181-186. 10.1007/s00380-008-1100-7.
Ghaderian SM, Akbarzadeh Najar R, Tabatabaei Panah AS: Genetic polymorphisms and plasma levels of matrix metalloproteinases and their relationships with developing acute myocardial infarction. Coron Artery Dis. 2010, 21: 330-335. 10.1097/MCA.0b013e32833ce065.
Chen Y, Nixon NB, Dawes PT, Mattey DL: Influence of variations across the MMP-1 and -3 genes on the serum levels of MMP-1 and -3 and disease activity in rheumatoid arthritis. Genes Immun. 2012, 13: 29-37. 10.1038/gene.2011.46.
Rutter JL, Mitchell TI, Butticè G: A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res. 1998, 58: 5321-5325.
Pearce E, Tregouet DA, Samnegård A: Haplotype effect of the matrix metalloproteinase-1 gene on risk of myocardial infarction. Circ Res. 2005, 97: 1070-1076. 10.1161/01.RES.0000189302.03303.11.
Affara M, Dunmore BJ, Sanders DA, Johnson N, Print CG, Charnock-Jones DS: MMP1 bimodal expression and differential response to inflammatory mediators is linked to promoter polymorphisms. BMC Genomics. 2011, 12: 43-10.1186/1471-2164-12-43.
Nojiri T, Morita H, Imai Y: Genetic variations of matrix metalloproteinase-1 and -3 promoter regions and their associations with susceptibility to myocardial infarction in Japanese. Int J Cardiol. 2003, 92: 181-186. 10.1016/S0167-5273(03)00100-1.
Ye S, Gale CR, Martyn CN: Variation in the matrix metalloproteinase-1 gene and risk of coronary heart disease. Eur Heart J. 2003, 24: 1668-1671. 10.1016/S0195-668X(03)00385-3.
Flex A, Gaetani E, Angelini F: Pro-inflammatory genetic profiles in subjects with peripheral arterial occlusive disease and critical limb ischemia. J Intern Med. 2007, 262: 124-130. 10.1111/j.1365-2796.2007.01791.x.
Horne BD, Camp NJ, Carlquist JF: Multiple-polymorphism associations of 7 matrix metalloproteinase and tissue inhibitor metalloproteinase genes with myocardial infarction and angiographic coronary artery disease. Am Heart J. 2007, 154: 751-758. 10.1016/j.ahj.2007.06.030.
Hlatky MA, Ashley E, Quertermous T: Matrix metalloproteinase circulating levels, genetic polymorphisms, and susceptibility to acute myocardial infarction among patients with coronary artery disease. Am Heart J. 2007, 154: 1043-1051. 10.1016/j.ahj.2007.06.042.
Han Y, Wu Z, Zhang X: Impact of matrix metalloproteinase-1 gene variations on risk of acute coronary syndrome. Coron Artery Dis. 2008, 19: 227-230. 10.1097/MCA.0b013e3282f9d3d8.
Montes AH, Valle-Garay E, Suarez-Zarracina T: The MMP1 (-16071G/2G) single nucleotide polymorphism associates with the HAART-related lipodystrophic syndrome. AIDS. 2010, 24: 2499-2506. 10.1097/QAD.0b013e32833e922c.
Abd-Allah SH, Shalaby SM, Pasha HF, El-Shal AS, Abou El-Saoud AM: Variation of matrix metalloproteinase 1 and 3 haplotypes and their serum levels in patients with rheumatoid arthritis and osteoarthritis. Genet Test Mol Biomarkers. 2012, 16: 15-20. 10.1089/gtmb.2011.0003.
Cheng YC, Kao WH, Mitchell BD: Genome-wide association scan identifies variants near matrix metalloproteinase (MMP) genes on chromosome 11q21-22 strongly associated with serum MMP-1 levels. Circ Cardiovasc Genet. 2009, 2: 329-337. 10.1161/CIRCGENETICS.108.834986.
WHO expert consultation: Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004, 363: 157-163.
Hsu LA, Ko YL, Hsu KH, Ko YH, Lee YS: Genetic variations in the cholesteryl ester transfer protein gene and high density lipoprotein cholesterol levels in Taiwanese Chinese. Hum Genet. 2002, 110: 57-63. 10.1007/s00439-001-0640-z.
Ko YL, Hsu LA, Hsu KH, Ko YH, Lee YS: The interactive effects of hepatic lipase gene promoter polymorphisms with gender and obesity on high-density-lipoprotein cholesterol levels in Taiwanese-Chinese. Atherosclerosis. 2004, 172: 135-142. 10.1016/j.atherosclerosis.2003.09.013.
Wu S, Hsu LA, Teng MS: Association of matrix metalloproteinase 9 genotypes and cardiovascular disease risk factors with serum matrix metalloproteinase 9 concentrations in Taiwanese individuals. Clin Chem Lab Med. 2010, 48: 543-549.
Wu TL, Tsao KC, Chang CP, Li CN, Sun CF, Wu JT: Development of ELISA on microplate for serum C-reactive protein and establishment of age-dependent normal reference range. Clin Chim Acta. 2002, 322: 163-168. 10.1016/S0009-8981(02)00172-9.
Chan EC, Chang CP, Wu TL, Wu JT: Enzymatic assay of homocysteine on microtiter plate or a TECAN analyzer using crude lysate containing recombinant methionine-lyase. Ann Clin Lab Sci. 2005, 35: 155-160.
Wu TL, Chen Tsai I, Chang PY: stablishment of an in-house ELISA and the reference range for serum amyloid A (SAA) Complementarity between SAA and C-reactive protein as markers of inflammation. Clin Chim Acta. 2007, 376: 72-76. 10.1016/j.cca.2006.07.012.
Wu S, Hsu LA, Cheng CF: Effect of obesity on the association between ATF3 gene haplotypes and C-reactive protein level in Taiwanese. Clin Chim Acta. 2011, 412: 1026-1031. 10.1016/j.cca.2011.02.011.
Hsu LA, Ko YL, Teng MS: Effect of obesity on the association between common variations in the HNF1A gene region and C-reactive protein level in Taiwanese. Clin Chim Acta. 2011, 412: 725-729. 10.1016/j.cca.2010.12.027.
Teng MS, Hsu LA, Wu S, Chang HH, Chou HH, Ko YL: Association between C-reactive protein gene haplotypes and C-reactive protein levels in Taiwanese: interaction with obesity. Atherosclerosis. 2009, 204: e64-e69. 10.1016/j.atherosclerosis.2008.10.034.
Hsu LA, Chang CJ, Wu S: Association between functional variants of the ICAM1 and CRP genes and metabolic syndrome in Taiwanese subjects. Metabolism. 2010, 59: 1710-1716. 10.1016/j.metabol.2010.04.004.
Nho YK, Ha E, Yu KI: Matrix metalloproteinase-1 promoter is associated with body mass index in Korean population with aged greater or equal to 50 years. Clin Chim Acta. 2008, 396: 14-17. 10.1016/j.cca.2008.06.012.
O'Hara A, Lim FL, Mazzatti DJ, Trayhurn P: Microarray analysis identifies matrix metalloproteinases (MMPs) as key genes whose expression is up-regulated in human adipocytes by macrophage-conditioned medium. Pflugers Arch. 2009, 458: 1103-1114. 10.1007/s00424-009-0693-8.
Li M, Xiao T, Zhang Y: Prognostic significance of matrix metalloproteinase-1 levels in peripheral plasma and tumour tissues of lung cancer patients. Lung Cancer. 2010, 69: 341-347. 10.1016/j.lungcan.2009.12.007.
Liu D, Duan W, Guo H, Xu X, Bai Y: Meta-analysis of associations between polymorphisms in the promoter regions of matrix metalloproteinases and the risk of colorectal cancer. Int J Colorectal Dis. 2011, 26: 1099-1105. 10.1007/s00384-011-1198-4.
Liu D, Guo H, Li Y, Xu X, Yang K, Bai Y: Association between polymorphisms in the promoter regions of matrix metalloproteinases (MMPs) and risk of cancer metastasis: a meta-analysis. PLoS One. 2012, 7: e31251-10.1371/journal.pone.0031251.